Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 14, 2007 Brian Lawler	Is Flamel Catching On? Flamel Technologies announces a deal with Wyeth to develop an improved formulation of a drug, but the financials, and details, remain secret.
The Motley Fool March 3, 2011 Brian Orelli	3 Cheers for an FDA Rejection German drugmaker Merck said that the Food and Drug Administration had turned down its multiple sclerosis drug cladribine. The pill would have competed with Novartis' Gilenya, which gained FDA approval last year.
The Motley Fool December 18, 2006 Brian Lawler	Nice: Flamel's Drug Approval With so much pessimism and internal hullabaloo, there weren't many investors willing to stick with Flamel, but those who did have been rewarded nicely.
The Motley Fool July 21, 2010 Brian Orelli	Biogen Looks Good Now, but What About Tomorrow? Biogen Idec saw revenue increase 11% and adjusted earnings per share jump almost 75%, which is all well and good, but the longer-term prospects for the company aren't nearly as impressive.
The Motley Fool June 3, 2010 Brian Orelli	When All Else Fails, Sue Your Competitors Biogen thinks its patent covers its competitors' drugs in addition to Avonex and has filed a lawsuit demanding royalties from its competitors.
The Motley Fool August 27, 2007 Rich Duprey	Flamel Falls Out of Compliance Market lashes out after a patient-compliance study shows that its only drug offers no better solution. Flamel has always been a risky investment, and that hasn't changed.
The Motley Fool March 5, 2008 Brian Lawler	Flamel in a Nutshell After a choppy year, Flamel says there are plenty of new possibilities in its pipeline.
The Motley Fool February 10, 2010 Brian Orelli	Icahn's Smiling -- Should We Be? Biogen Idec's fourth quarter results must have made Carl Icahn smile. But the guidance for next year gives pause.
The Motley Fool September 21, 2006 Brian Lawler	Sayonara, Serono The tiny, struggling drugmaker succumbs to a surprise buyout by German pharmaceutical company Merck KGaA. Investors, take note.
The Motley Fool November 29, 2010 Brian Orelli	There's Still Only One Merck KGaA's oral MS drug delay is Novartis' gain.
The Motley Fool June 15, 2005 Charly Travers	Flamel's CEO Must Go Because the biotech firm has disappointed, investors have understandably not rewarded its lousy results. Flamel's shareholders must vote to remove a management road block to the company's success.
The Motley Fool February 26, 2009 Robert Steyer	Merck KGaA's Good Chemistry This German conglomerate successfully mixes drugs and chemicals.
The Motley Fool November 24, 2009 Brian Orelli	4 Platform Drugmakers to Invest In Elan ... Alkermes... Flamel Technologies... etc.
The Motley Fool October 25, 2005 Jason Mac Gurn	Visualizing Value for Flamel Those interested in the long-term potential of this biotech's business should be searching for signs that its technological potential will evolve to provide value for shareholders.
The Motley Fool July 30, 2004 W.D. Crotty	This Nanotech Deserves Respect While the stock recently hit some potholes, Flamel still looks good for the future.
The Motley Fool August 8, 2008 Brian Lawler	Flamel Tries to Get It in Gear Flamel has done a good job of reducing its cash burn, allowing it to buy some time to work on the compounds in its pipeline.
The Motley Fool November 2, 2007 Brian Lawler	Flamel Plays Close to the Vest With only one sustainable source of revenue, the drug developer tries to curtail spending and get new compounds into the pipeline. Investors, take note.
The Motley Fool October 16, 2007 Brian Lawler	Questions Surround a Biogen Deal Rumors swirl around Biogen after it publicly announces that it's for sale. Investors, take note.
The Motley Fool May 12, 2011 Brian Orelli	Teva's Mixed Bag Diversification sure helps.
The Motley Fool October 27, 2010 Brian Orelli	Biogen Idec's Fight-Back Plan Novartis' Gilenya is coming, but Biogen has a backup plan.
The Motley Fool September 20, 2004 Wherrett & Yelovich	Flamel Shot Down The company's nano product loses some of its shine. The stock fell more than 25% after Bristol-Myers Squibb pulled out of its partnership to develop Basulin.
The Motley Fool May 12, 2010 Brian Orelli	Is Merck a Buy? Short term it's hard to say, but for the long term, its pipeline looks strong.
The Motley Fool April 29, 2008 Brian Orelli	Merck's Recovery Flushed Down Merck's best hope at recovery fails approval by the FDA.
The Motley Fool May 26, 2010 Brian Orelli	Blockbuster Drugs Aimed at Busting MS Multiple sclerosis is a large market with more entrants coming.
The Motley Fool October 19, 2006 Brian Lawler	Marking Time at Serono Things still look good for investors in this soon-to-be-acquired Swiss pharma.
The Motley Fool September 6, 2005 Rich Duprey	Flamel's Dubious Future French nanotech pioneer loses deal with TAP Pharmaceuticals for heartburn formulation. There's just too much fog facing this company for investors to see clearly ahead.
The Motley Fool October 25, 2007 Brian Lawler	Flamel Gets Upbeat News About Coreg Flamel Technologies is earning more than had been calculated from its lead drug, but the company still isn't profitable. Investors, take note.
The Motley Fool July 8, 2004 W.D. Crotty	From Flameout to Bargain Despite its stock decline, there's a lot to like about French biopharmaceutical Flamel.
The Motley Fool September 27, 2005 Jack Uldrich	A Ray of Hope for Flamel? New hepatitis C treatment offers a ray of hope to the ailing nanotech company. Unfortunately, this news does not guarantee sunnier days ahead.
The Motley Fool April 29, 2011 Brian Orelli	Oral Multiple Sclerosis Drugs Heat Up Watch out Novartis and Gilenya.
The Motley Fool October 29, 2004 W.D. Crotty	Future Looking Up for Flamel As the nanotech/biotech company earns a profit -- keep an eye on two drugs in phase 3 trials.
The Motley Fool April 28, 2008 Brian Lawler	Flamel Inches Forward New sales data arrives for one lead drug, new promising data for another.
The Motley Fool June 6, 2005 Rich Duprey	Flamel Inflames Passions The nanotech firm faces a fiery shareholder fight. Is Flamel doing enough to promote its medical technologies? Management says yes, but shareholders disagree. Here's a survey of the battlefield.
The Motley Fool May 9, 2006 Brian Gorman	No Quick Fix for Merck Two biotech purchases won't bolster the drug giant's pipeline, but they promise a longer-term payoff. Investors will have to be patient.
The Motley Fool October 31, 2011 Brian Orelli	When You've Got It, You've Got It Biogen keeps its good-news streak going.
Chemistry World August 24, 2012 Andrew Turley	Merck KGaA buys cell culture company Merck KGaA has struck a deal to buy German company Biochrom, which makes cell culture media and buffer solutions, for an undisclosed price.
The Motley Fool May 15, 2008 Brian Lawler	What's Cooking at Flamel? The drugmaker makes finding partners to help pay for its hepatitis C and diabetes compounds a top priority.
The Motley Fool February 11, 2008 Brian Lawler	No Fire Fueling Flamel's Top Drug Flamel Technologies had a rough 2007; and with only one drug determining its near-term success, investors should be cautious of this drugmaker.
The Motley Fool February 29, 2008 Brian Orelli	Merck's Complicated Partnerships Merck has decided to continue its complicated partnership with AstraZeneca for at least a few more years.
The Motley Fool May 5, 2010 Brian Orelli	Doubled Revenue, but Not High Growth An acquisition and some rearrangements make Merck's revenue line sound better than it is.
The Motley Fool October 18, 2007 Brian Lawler	Genzyme Shows Off a Drug Candidate A top compound in development could become an important MS treatment.
The Motley Fool September 18, 2007 Brian Orelli	New York Tag-Teams Merck Both the city and state of New York sue Merck over Vioxx payments, alleging the big pharma defrauded Medicaid and other government agencies, by hiding problems related to its painkilling drug.
The Motley Fool May 13, 2008 Brian Orelli	Is Merck Keeping Its Enemies Close? The drugmaker strikes a deal with an Indian generic company.
The Motley Fool July 29, 2009 Brian Orelli	Ignore These Companies at Your Peril You may not want to invest in them, but don't ignore them.
The Motley Fool May 21, 2008 Brian Orelli	OK, Last Vioxx Settlement, Honest! What's another $58 million when Merck's already forking over $4.85 billion?
The Motley Fool July 30, 2010 Brian Orelli	It's Hard to Get Excited About 92% Revenue Growth Especially when revenue dropped on a comparable basis.
The Motley Fool March 4, 2005 Rich Duprey	Flamel Flames Out Again Nanotech regains rights to herpes treatment as partnership with pharma Biovail fails.
The Motley Fool December 21, 2006 Brian Lawler	Dueling Fools: Merck Bull Rebuttal Plenty of cash. Big pipeline. Not to worry. The future can't be predicted, but Merck's history shows its ability to weather even the toughest pharmaceutical-development environments.
The Motley Fool October 5, 2007 Brian Orelli	Merck's Next Blockbuster? Merck's cholesterol drug comes back from phase 2 testing with no side effects. Investors, take note.
The Motley Fool February 13, 2009 Brian Orelli	The Easy Way to Develop Drugs Merck buys a pipeline of follow-on biologics and a building to produce them.